Inclusion Criteria:

• Age ≥ 18 years.
• Histological confirmation of glioblastoma, IDH-wildtype; or Grade 3 or 4, IDH1/2 mutant astrocytoma (2021 WHO classification).
• Disease progression after previous treatment for glioma with radiation and chemotherapy.
• Eligible for re-irradiation as a part of routine clinical care 3.1.6 ECOG Performance Status (PS) ≤ 2 (Appendix I).
• Negative pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
• Provide written informed consent.
• Willing to return for follow-up (during the Active Monitoring Phase of the study).
• Willing to provide tissue and blood samples for correlative research purposes (see Section 6).
• Adequate organ and bone marrow function as defined by the following laboratory values obtained ≤14 days prior to registration:
  • Hemoglobin > 9.0 g/dL;
  • Leukocytes > 3.0 x 10^9/L;
  • Absolute neutrophil count > 1.5 x 10^9/L;
  • Platelets > 100 x 10^9/L;
  • INR < 1.5 x upper limit of normal (ULN)*;
  • aPTT < 1.5 x ULN;
  • Total bilirubin ≤ 1.5 x ULN and <3 mg/dL for patients with Gilbert’s disease;
  • AST (SGOT) & ALT (SGPT) ≤ 3 x ULN. i. Creatinine ≤ 1.5 x ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/minute.
• Minimum life expectancy of at least 3 months.
• Willing to take light-protective measures during the study and for two weeks after their last dose of WSD0628.
• For patients enrolled on Part B2: Dose Expansion, Brain Tumor Penetration Cohort: plan for radiosurgery and surgical resection as part of routine clinical care.

Exclusion Criteria: 

• < 18 years old. 
• Pregnant. 

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 5/9/23. Questions regarding updates should be directed to the study team contact.